SCHEMBL22717119

SCHEMBL22717119

CCCCCC(=O)OS(=O)(=O)CCN

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.44
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
THRB P10828 1/20 0.42
CNR1 P21554 1/20 0.42
LMNA P02545 3/20 0.42
PAM P19021 2/20 0.41
CYP1A2 P05177 1/20 0.40
MAPK1 P28482 1/20 0.40
CES2 O00748 4/20 0.39
CES1 P23141 4/20 0.39
TSHR P16473 1/20 0.39
DNM1 Q05193 1/20 0.38
AKR1B1 P15121 1/20 0.38
NAAA Q02083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31051576 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL15874693 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL3634120 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL29606730 0.98 DGKA (0.43) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL17085777 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL5393249 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL5156066 0.98 DGKA (0.47) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL1982508 0.97 DGKA (0.46) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL1987495 0.97 DGKA (0.46) DGKAMAPTALDH1A1THRBCNR1
SCHEMBL22325579 0.97 DGKA (0.46) DGKAMAPTALDH1A1THRBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676435-A1 PERSONAL CARE COMPOSITION The Procter & Gamble Company (US) 2026-01-14 EP claimed
EP-4676436-A1 PERSONAL CARE COMPOSITION The Procter & Gamble Company (US) 2026-01-14 EP claimed
WO-2024187075-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2024-09-12 WO claimed
US-20240299285-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY 2024-09-12 US claimed
WO-2024187076-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2024-09-12 WO claimed
US-20240299272-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY 2024-09-12 US claimed
EP-3551162-B1 COMPOSITION SUITABLE FOR CLEANSING OREAL (FR) 2024-06-26 EP claimed
CN-113892029-A Mass spectrometry method for detecting metabolites 梅塔博隆股份有限公司 2022-01-04 CN claimed
EP-4731176-A1 COMPOSITION COMPRISING GLYCOLIPID, TAURATE SURFACTANT, AND AMINO ACID SURFACTANT L'OREAL (FR) 2026-04-29 EP disclosed
EP-4731173-A1 COMPOSITION COMPRISING LOW MOLECULAR WEIGHT POLYLYSINE AND GLYCOLIPIDS L'OREAL (FR) 2026-04-29 EP disclosed
US-20260076887-A1 PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS PROCTER & GAMBLE (US) 2026-03-19 US disclosed
US-20260062648-A1 Dissolvable Solid Cleansing Articles Containing Taurate Surfactants PROCTER & GAMBLE (US) 2026-03-05 US disclosed
EP-4676435-A1 PERSONAL CARE COMPOSITION The Procter & Gamble Company (US) 2026-01-14 EP disclosed
EP-4676436-A1 PERSONAL CARE COMPOSITION The Procter & Gamble Company (US) 2026-01-14 EP disclosed
WO-2024187075-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2024-09-12 WO disclosed
US-20240299285-A1 PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY 2024-09-12 US disclosed
EP-3551162-B1 COMPOSITION SUITABLE FOR CLEANSING OREAL (FR) 2024-06-26 EP disclosed
EP-3977112-A1 MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES Metabolon Inc. (US) 2022-04-06 EP disclosed
CN-113892029-A Mass spectrometry method for detecting metabolites 梅塔博隆股份有限公司 2022-01-04 CN disclosed
WO-2020242744-A1 MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES METABOLON, INC. (US) 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299272-A1 PERSONAL CARE COMPOSITION TAF1, POLH, KAT7 DGKA 2670/4885MAPT 215/4885ALDH1A1 4394/4885
US-20260062648-A1 Dissolvable Solid Cleansing Articles Containing Taurate Surfactants SLC6A6, PHOSPHO1, SGMS2 DGKA 222/4885MAPT 30/4885ALDH1A1 4124/4885
US-20260076887-A1 PERSONAL CARE COMPOSITIONS CONTAINING TAILORED MONOLIPID-RHAMNOLIPIDS AND SULFATE-FREE SURFACTANTS CUTA, PHOSPHO1, MGLL DGKA 2226/4885MAPT 3145/4885ALDH1A1 4478/4885
US-20240299285-A1 PERSONAL CARE COMPOSITION KAT7, SMURF1, CUTA DGKA 2070/4885MAPT 83/4885ALDH1A1 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.